Original Research
Published on 01 Nov 2024
Long-term efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a prospective real-world cohort study in China
in Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
- 121 views